Onco360成为Revuforj的国家药房伙伴,Revuforj是第一个针对特定急性白血病的核准药物。 Onco360 becomes national pharmacy partner for Revuforj, the first approved drug for specific acute leukemias.

Onco360是一家专科药店,已被选为Revuforj(revummenib)的国家药店伙伴,这是第一个被批准用KMT2A基因转基因治疗1岁及以上病人复发或复发性急性白血病的经批准抑制剂。 Onco360, a specialty pharmacy, has been chosen as the national pharmacy partner for Revuforj (revumenib), the first approved menin inhibitor for treating relapsed or refractory acute leukemias with KMT2A gene translocations in patients aged 1 and older. 美国食品和药物管理局的批准是基于一项试验,显示完整缓解率为21. 2%. The FDA approval is based on a trial showing a 21.2% complete remission rate. Revuforj以药片形式出现,为较年轻的病人提供口服治疗,并用盒式警告器警告分化综合症。 Revuforj comes in tablets and an oral solution for younger patients, with a boxed warning for differentiation syndrome.